FDA Grants Orphan Drug Designation to SH-110 for Oral Suspension in Glioma

Read full article on OncologyLive:

  • SH-110, a liquid formulation for glioma, addresses swallowing difficulties, enhancing safety and convenience for patients and caregivers.
  • Gliomas are associated with high morbidity and mortality, with quality of life being a primary treatment consideration for most patients.

LATEST NEWS